The study objective was to investigate the potential of the Consciousness Energy Treated test formulation on vital organs like bones, heart, liver, lungs, and brain using various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Su-Mei Chen Liu, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental groups of Biofield Treated Medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 53.5% (at 0.1 µg/mL), 127.9% (at 10 µg/mL), and 53.3% (at 25 µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI group showed 144% and 87.9% restoration of cell viability at 1 and 10 µg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 195%, 242.5%, and 117.5% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 0.1 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 94.2% (at 10 µg/mL) in the BT-Med + BT-TI; while 87.6%, 90.5%, and 90.3% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 249.5% and 167.4% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 94.5% (at 0.1 µg/mL) and 77.7% (at 25 µg/mL) in the BT-Med + BT-TI groups, respectively; while 58.4% (at 10 µg/mL) in the BT-Med + BT-TI group compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 70.3% and 106% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively 1 µg/mL compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 95.9% in the UT-Med + BT-TI group at 0.1 µg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 58.4% and 135.9% in the BT-Med + BT-TI group at 10 and 25 µg/mL, respectively; while 72.8% (at 25 µg/mL) in the BT-Med + UT-TI group as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 373.2% (at 1 µg/mL) and 263.1% (at 10 µg/mL) in the BT-Med + UT-TI group; while 318.4% (at 1 µg/mL) and 224.4% (at 10 µg/mL) in the BT-Med + BT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Energy Treated test formulation has significantly improved the bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones.
